| Advantage Home Health And Hospice | |
| 100 Mt Allen Drive Room 3068, Mechanicsburg, Pennsylvania 17055 | |
| (717) 590-8878 | |
| Name | Advantage Home Health And Hospice |
|---|---|
| Location | 100 Mt Allen Drive Room 3068, Mechanicsburg, Pennsylvania |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 397129 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 17007, 17011, 17013, 17015, 17025, 17036, 17050, 17055, 17057, 17062, 17068, 17081, 17090, 17103, 17110, 17113, 17201, 17339, 17365, 17372 |
| NPI Number | 1508139817 |
| Organization Name | ADVANTAGE HOME HEALTH SERVICES, EAST, LLC |
| Address | 100 Mount Allen Dr Rm 3068, Mechanicsburg, PA 17055 |
| Phone Number | 717-590-8878 |
News Archive
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.
After thyroid cancer surgery, many patients should be in the position of deciding with their doctors whether to pursue treatment with radioactive iodine to help ease long-term follow-up and offer reassurance that the cancer is gone.
Rhabdomyosarcoma is a malignant soft tissue tumor in the muscle tissue of children and adolescents. About 20 children are diagnosed with rhabdomyosarcoma per year in the Netherlands. "Metastases in these children are often found in the lungs," says professor Hans Merks of the Princess Máxima Center for Pediatric Oncology, who led the study.
› Verified 6 days ago
| Quality Rating: |
News Archive
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.
After thyroid cancer surgery, many patients should be in the position of deciding with their doctors whether to pursue treatment with radioactive iodine to help ease long-term follow-up and offer reassurance that the cancer is gone.
Rhabdomyosarcoma is a malignant soft tissue tumor in the muscle tissue of children and adolescents. About 20 children are diagnosed with rhabdomyosarcoma per year in the Netherlands. "Metastases in these children are often found in the lungs," says professor Hans Merks of the Princess Máxima Center for Pediatric Oncology, who led the study.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 100 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.6 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 100 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 76.5 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 87.7 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | - | 96.4 |
News Archive
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.
After thyroid cancer surgery, many patients should be in the position of deciding with their doctors whether to pursue treatment with radioactive iodine to help ease long-term follow-up and offer reassurance that the cancer is gone.
Rhabdomyosarcoma is a malignant soft tissue tumor in the muscle tissue of children and adolescents. About 20 children are diagnosed with rhabdomyosarcoma per year in the Netherlands. "Metastases in these children are often found in the lungs," says professor Hans Merks of the Princess Máxima Center for Pediatric Oncology, who led the study.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 70.3 | 79.6 |
| How often patients got better at getting in and out of bed | 79.9 | 81.1 |
| How often patients got better at bathing | 73 | 82.3 |
| How often patients’ breathing improved | 60.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 62.7 | 75 |
| How often home health patients had to be admitted to the hospital | 22.6 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 15.5 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 100 | 94 |
News Archive
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.
After thyroid cancer surgery, many patients should be in the position of deciding with their doctors whether to pursue treatment with radioactive iodine to help ease long-term follow-up and offer reassurance that the cancer is gone.
Rhabdomyosarcoma is a malignant soft tissue tumor in the muscle tissue of children and adolescents. About 20 children are diagnosed with rhabdomyosarcoma per year in the Netherlands. "Metastases in these children are often found in the lungs," says professor Hans Merks of the Princess Máxima Center for Pediatric Oncology, who led the study.
› Verified 6 days ago
News Archive
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.
After thyroid cancer surgery, many patients should be in the position of deciding with their doctors whether to pursue treatment with radioactive iodine to help ease long-term follow-up and offer reassurance that the cancer is gone.
Rhabdomyosarcoma is a malignant soft tissue tumor in the muscle tissue of children and adolescents. About 20 children are diagnosed with rhabdomyosarcoma per year in the Netherlands. "Metastases in these children are often found in the lungs," says professor Hans Merks of the Princess Máxima Center for Pediatric Oncology, who led the study.
› Verified 6 days ago
Residential Home Health Of Carlisle, Llc Location: 100 Sterling Parkway Suite 110, Mechanicsburg, Pennsylvania 17050 Ratings: Phone: (888) 923-5842 | |
Advantage Home Health And Hospice Location: 100 Mt Allen Drive Room 3068, Mechanicsburg, Pennsylvania 17055 Ratings: Phone: (717) 590-8878 | |
Bayada Home Health Care, Inc. Location: 5001 Louise Drive Suite 203, Mechanicsburg, Pennsylvania 17055 Ratings: NA Phone: (717) 795-5950 |